[Influence of the -866G/A polymorphism of the UCP2 gene on an obese pediatric population]

R Zurbano1, M C Ochoa, M J Moreno-Aliaga

  • 1Departamento de Fisiología y Nutrición, Universidad de Navarra, Pamplona, España.

Nutricion Hospitalaria
|March 28, 2006
PubMed

Insights

The -866G/A mutation in the UCP2 gene is linked to increased subcutaneous fat in obese children. This finding suggests a potential genetic marker for obesity-related phenotypes in pediatric populations.

Area of Science:

  • Genetics and Molecular Biology
  • Pediatrics
  • Obesity Research

Background:

  • Obesity is a complex multifactorial disease.
  • The uncoupling protein 2 (UCP2) gene is implicated in metabolic processes and body composition.
  • Previous studies on the UCP2 -866G/A polymorphism and obesity risk have yielded contradictory results.

Purpose of the Study:

  • To determine the prevalence of the UCP2 -866G/A gene mutation in obese children from Navarra.
  • To investigate the association between this UCP2 gene polymorphism and phenotypic characteristics of obesity in the studied cohort.

Main Methods:

  • A cohort of 125 obese children (11-12 years old) was recruited.
  • Anthropometric measurements (BMI, skinfolds) and body fat percentage were assessed.
  • DNA analysis using PCR and BstUI digestion identified UCP2 genotypes; plasma biomarkers were also measured.

Main Results:

  • The frequency of the UCP2 -866A allele was 0.404.
  • Children carrying the -866A allele exhibited significantly higher tricipital and subscapular skinfold thickness.
  • No significant differences in plasma glucose, insulin, leptin, or cholesterol levels were observed between carriers and non-carriers.

Conclusions:

  • The UCP2 -866G/A polymorphism is associated with increased subcutaneous fat in obese children.
  • The -866A allele may indicate a predisposition to higher subcutaneous fat accumulation in pediatric obesity.
  • Further research is warranted to elucidate the precise role of UCP2 in obesity pathogenesis.
Abstract

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...